Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.
Advertisement

Related Content

EU Pharma Ups Share Buybacks In 2012
“Arimidex Direct” Program Will Provide Branded Cancer Drug To U.S. Patients For $40 A Month
AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds
Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2
Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2
For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms
At PSA, Meet The New Deal-Makers (Part 2)
At PSA, Meet The New Deal-Makers (Part 1)
R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS071770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel